Copied
 
 
2023, DKK
10.06.2024
Bruttoresultat

17.305'

Primær drift

-77.468'

Årets resultat

-61.863'

Aktiver

66.890'

Kortfristede aktiver

57.457'

Egenkapital

-55.779'

Afkastningsgrad

-116 %

Soliditetsgrad

-83 %

Likviditetsgrad

47 %

Resultat
10.06.2024
Årsrapport
2023
10.06.2024
2022
07.06.2023
2021
05.07.2022
2020
14.06.2021
2019
25.06.2020
2018
31.05.2019
2017
31.05.2018
2016
31.05.2017
2015
03.06.2016
Nettoomsætning90.047.899
Bruttoresultat17.305.00018.886.00040.956.00040.550.00031.384.00038.193.00048.868.69550.731.4600
Resultat af primær drift-77.468.000-100.897.000-38.046.000-20.778.000-25.247.000-12.460.0003.775.9734.195.2746.707.234
Indtægter af kapitalandele (tilknyttede og associerede) 000000000
Finansielle indtægter46.000016.00032.00061.0000224.740120.10832.452
Finansieringsomkostninger000000000
Andre finansielle omkostninger-4.823.000-3.448.000-1.951.000-1.077.000-1.052.000-797.000-442.657-515.721-849.238
Resultat før skat-82.245.000-104.345.000-39.981.000-21.823.000-26.238.000-13.257.0003.558.0563.799.6615.890.448
Resultat-61.863.000-81.736.000-31.247.000-17.026.000-20.471.000-10.329.0002.776.7772.967.1444.522.922
Forslag til udbytte0000000-5.000.0000
Aktiver
10.06.2024
Årsrapport
2023
10.06.2024
2022
07.06.2023
2021
05.07.2022
2020
14.06.2021
2019
25.06.2020
2018
31.05.2019
2017
31.05.2018
2016
31.05.2017
2015
03.06.2016
Kortfristede varebeholdninger2.508.00031.910.00033.658.00032.514.00023.701.00019.997.00017.416.24914.472.46115.209.360
Kortfristede tilgodehavender fra salg og tjenesteydelser 54.949.00054.083.00018.468.00012.894.00015.449.0007.590.0007.024.86710.476.33215.126.253
Likvider030.00000019.000001.636.442
Kortfristede aktiver57.457.00086.023.00052.126.00045.408.00039.150.00027.606.00024.441.11624.948.79331.972.055
Immaterielle aktiver og goodwill000000000
Finansielle anlægsaktiver00000000146.613
Materielle aktiver9.433.00032.966.00045.867.00050.930.00049.797.00047.702.00035.684.07920.747.13714.291.240
Langfristede aktiver9.433.00032.966.00045.867.00050.930.00049.797.00047.702.00035.684.07920.747.13714.437.853
Aktiver66.890.000118.989.00097.993.00096.338.00088.947.00075.308.00060.125.19545.695.93046.409.908
Aktiver
10.06.2024
Passiver
10.06.2024
Årsrapport
2023
10.06.2024
2022
07.06.2023
2021
05.07.2022
2020
14.06.2021
2019
25.06.2020
2018
31.05.2019
2017
31.05.2018
2016
31.05.2017
2015
03.06.2016
Forslag til udbytte00000005.000.0000
Egenkapital-55.779.00018.156.00024.892.00011.139.0008.161.0008.632.00018.960.87121.184.09518.216.953
Hensatte forpligtelser00961.0002.426.0001.943.0001.145.000652.167408.737157.282
Langfristet gæld til banker000000000
Anden langfristet gæld00000000
Leverandører af varer og tjenesteydelser1.188.0005.468.0005.739.0002.904.0005.446.0002.980.0005.239.6543.920.7794.520.048
Kortfristede forpligtelser121.865.00099.711.00070.673.00076.112.00074.956.00063.021.00037.654.14920.901.61724.308.516
Gældsforpligtelser122.669.000100.833.00072.140.00082.773.00078.843.00065.531.00040.512.15724.103.09828.035.673
Forpligtelser122.669.000100.833.00072.140.00082.773.00078.843.00065.531.00040.512.15724.103.09828.035.673
Passiver66.890.000118.989.00097.993.00096.338.00088.947.00075.308.00060.125.19545.695.93046.409.908
Passiver
10.06.2024
Nøgletal
10.06.2024
Årsrapport
2023
10.06.2024
2022
07.06.2023
2021
05.07.2022
2020
14.06.2021
2019
25.06.2020
2018
31.05.2019
2017
31.05.2018
2016
31.05.2017
2015
03.06.2016
Afkastningsgrad -115,8 %-84,8 %-38,8 %-21,6 %-28,4 %-16,5 %6,3 %9,2 %14,5 %
Dækningsgrad Na.Na.Na.Na.Na.Na.Na.Na.Na.
Resultatgrad Na.Na.Na.Na.Na.Na.Na.Na.5,0 %
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.5,9
Egenkapitals-forretning 110,9 %-450,2 %-125,5 %-152,9 %-250,8 %-119,7 %14,6 %14,0 %24,8 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.168,5 %Na.
Gældsdæknings-nøgletal Na.Na.Na.Na.Na.Na.Na.Na.Na.
Soliditestgrad -83,4 %15,3 %25,4 %11,6 %9,2 %11,5 %31,5 %46,4 %39,3 %
Likviditetsgrad 47,1 %86,3 %73,8 %59,7 %52,2 %43,8 %64,9 %119,4 %131,5 %
Resultat
10.06.2024
Gæld
10.06.2024
Årsrapport
10.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 10.06.2024)
Information om virksomhedens regnskabsklasse:This annual report has been prepared in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium). The accounting policies applied to the financial statements are consistent with those applied last year. Recognition and measurement of assets and liabilities reflect that the Company is preparing the financial statement without the going concern assumption as the intention is to shut down the activities of the Company, thus assets and liabilities are measured at net realisable value.
Oplysning om pantsætninger og sikkerhedsstillelser:14 Assets charged and collateralThe Entity has provided guarantees under which the guarantors assume joint and several liability for Group enterprises' net debt with bank and credit institutions. The Group’s total net debt in relation to this guarantee amounts to 3,714 mDKK at 31.12.2023. Mortgage debt are secured by way of mortgage on properties. The carrying amount of mortgaged properties is 8,420 kDKK at 31.12.2023.
Beretning
10.06.2024
Dato for ledelsens godkendelse af årsrapporten:2024-06-05
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual circumstances affecting recognition and measurementAs mentioned above, Management of Orifarm Group decided to discontinue the activities in Viminco A/S with complete full site exit in 2024. The goods produced by Viminco A/S has been transferred to the Orifarm site in Hobro and Poland.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Viminco A/S for the financial year 01. 01. 2023 - 31. 12. 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesViminco A/S is part of Orifarm Group, which is a dynamic international player in the healthcare business. Viminco A/S is a contract developer as well as manufacturer of niche and specialty pharmaceuticals. The activities was discontinued by the end of 2023 with complete full site exit in 2024.